CAMBRIDGE, Mass., April 20, 2009 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NasdaqGM:MNTA - News), a biotechnology company specializing in the characterization and engineering of complex mixture drugs, today announced results from a preclinical study of its novel oncology drug candidate, M402. The data showed that M402 in combination with chemotherapeutic agents inhibited spontaneous tumor metastasis in a murine metastatic breast carcinoma model. The results were presented in a poster session titled ``M-ONC 402 - A Non-Anticoagulant Low Molecular Weight Heparin Inhibits Tumor Metastasis'' (abstract #281) on Sunday, April 19, 2009 at the 100th Annual Meeting of the American Association for Cancer Research (AACR), in Denver, Colorado.
